Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).
Yusuke Sano, Masato Ozaka, Shuichi Aoki, Shogo Nomura, Noriko Mitome, Haruhiko Fukuda, Takahiro Mizui, Keiko Kamei, Masaaki Murakawa, Hidetoshi Eguchi, Manabu Kawai, Hirofumi Shirakawa, Shintaro Yagi, Nobumasa Mizuno, Amane Takahashi, Hidenori Takahashi, Naoki Ikenaga, Naohiro Okano, Shigeru Marubashi, Yuichi Nagakawa, Shinjiro Kobayashi, Taro Okazaki, Kazuaki Harada, Hirofumi Akita, Toru Otsuru, Shingo Kagawa, Seiko Hirono, Satoru Seo, Shiho Arima, Naoto Gotohda, Tsutomu Fujii, Etsuro Hatano, Michiaki Unno, Makoto Ueno, Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group
Jpn J Clin Oncol 56(7) 904-909
摘要
摘要
Neoadjuvant gemcitabine plus S-1 (GS) followed by surgery and adjuvant S-1 is the standard of care for resectable pancreatic cancer. Since ~73% of newly diagnosed pancreatic cancer patients are aged ≥70, effective treatments are strongly needed in this geriatric population. In unresectable pancreatic cancer, gemcitabine plus nab-paclitaxel (GnP) is widely used, even among geriatric patients. To evaluate the survival advantage of neoadjuvant GnP over GS for geriatric patients with resectable pancreatic cancer, an open-label randomized phase III trial (JCOG2101C) has been initiated since October 2022. A total of 400 patients will be enrolled from 28 institutions within 3 years. The primary endpoint is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCTs031220351 [https://jrct.mhlw.go.jp/latest-detail/jRCTs031220351].
KM 提取结果
0 个 Figure · 0 个 KM 面板